Retatrutide Cuts Sleep Apnea Symptoms in 691-Patient Trials as Weight Loss Reaches 20%
Updated
Updated · Fox News · Oct 28
Retatrutide Cuts Sleep Apnea Symptoms in 691-Patient Trials as Weight Loss Reaches 20%
3 articles · Updated · Fox News · Oct 28
Summary
Two phase 3 trials in 691 adults found Eli Lilly’s experimental obesity drug retatrutide significantly reduced obstructive sleep apnea severity versus placebo over 80 weeks.
Up to 68% of participants saw more than a 50% improvement in symptoms, while body weight fell 12% to nearly 20%, suggesting the apnea benefit was closely tied to weight loss.
Hypoxic burden dropped about 75% in patients without type 2 diabetes and 65% in those with it; researchers also reported lower blood pressure, LDL cholesterol and inflammation.
About 25% of participants without diabetes and 15% with diabetes saw sleep apnea resolve, and CPAP use generally declined during the study.
Retatrutide is still unapproved by the FDA, which has warned against illegal online versions, and researchers said longer-term safety and cardiovascular outcomes still need study.